Company: RDPTF
Filing Date: 2025-09-18
Form Type: 20-F
Source: 0001213900-25-088699
Chunk: 114

Company: Radiopharm Theranostics Ltd
Filing Date: 2025-09-18
Form: 20-F
Item: Item 6
Chunk 114
---
 addition, our board of directors has determined that Hester Larkin and
Noel Donnelly meet the criteria for independence of audit committee members as set forth in SEC and Nasdaq rules. While Ian Turner
is not independent under the applicable rules of the SEC and Nasdaq, the Board of Directors has determined that his appointment as a
member of the audit committee is in the best interest of Radiopharm and its shareholders and, in accordance with Nasdaq Listing Rule
5605(c)(2)(B), he may serve on the audit committee no longer than two years.

Remuneration and Nomination Committee

Our Remuneration and Nomination
Committee is comprised of non-executive directors and currently consists of the following: Hester Larkin and Leila Alland.

The committee reviews and
determines our remuneration policy and structure annually to ensure it remains aligned to business needs and meets our remuneration principles.
In particular, the board aims to ensure that remuneration practices are:

  competitive and reasonable, enabling Radiopharm to attract and retain key talent;  

  aligned to Radiopharm’s strategic and business objectives and the creation of shareholder value;  

  transparent and easily understood; and  

  acceptable to shareholders.  

Corporate Governance Requirements under Nasdaq listing rules.

As Radiopharm is incorporated
in Australia, we are allowed to follow Australian “home country” corporate governance practices in lieu of the otherwise applicable
Nasdaq corporate governance standards, as long as we disclose each requirement of Rule 5600 that we do not follow and describe the home
country practice we follow in lieu of the relevant Nasdaq corporate governance standards. We intend to take all actions necessary to maintain
compliance with applicable corporate governance requirements under the rules adopted by the SEC and listing standards of Nasdaq. We follow
Australian corporate governance practices in lieu of the corporate governance requirements of the Nasdaq Marketplace Rules in respect
of:

  Nasdaq requirement under Rule 5605(d) that a compensation committee be constituted — The ASX Listing Rules do not have an express requirement that each issuer listed on ASX have a compensation ...  

  Nasdaq requirement under Rule 5605(e) that a nominations committee be constituted — The ASX Listing Rules do not have an express requirement that each issuer listed on ASX have a nominations co...  

  Nasdaq requirement under Rule 5620(c) that a quorum consist of holders of 33 1/3% of the outstanding ordinary shares — The ASX